Canopy Growth (CGC) Q1 2027 Earnings Call Transcript

Canopy Growth reported Q1 fiscal 2027 net revenue of CAD 81.2 million (+13% YoY), with adjusted gross margin rising 600 bps to 31% and adjusted EBITDA loss improving 59% YoY to CAD 3.2 million. Cannabis segment adjusted gross margin increased to 26% (vs 24%), while Storz & Bickel gross margin jumped to 48% (from 29%), aided by cost actions and tariff refunds; net loss fell 68% to CAD 14.6 million. Management reiterated expectations for YoY revenue growth throughout fiscal 2027 and is targeting margin expansion to the mid-30s (adjusted) into year-end, supported by MTL integration synergies (CAD 8 million of CAD 10 million executed) and EU GMP certifications aimed at accelerating Europe/international sales.

Analysis

The market should read this as a sequencing story, not a clean earnings beat. Near term, the shares can drift higher because the business is moving from “survive” to “self-help” with margin leverage coming from integration, but the quality of that improvement matters: a meaningful slice of the gross margin expansion is still a mix of mix-shift, supply-chain cleanup, and temporary items, so the durability will only be proven once cultivation gains show up in Q2/Q3. That makes the next two quarters the key catalyst window; if mid-30s adjusted gross margin is not visible by late summer, the turnaround narrative loses credibility fast.

The biggest second-order winner is the European medical platform, not the domestic Canadian franchise. EU GMP qualification plus consistent flower supply creates a real barrier to entry in Poland/UK, which should pressure smaller EU importers and lower-quality Canadian exporters that rely on spot supply rather than vertically controlled output. In Canada, the improved premium flower position matters because it lets CGC defend price/mix without relying solely on veteran reimbursement economics, but that also means competitors with weaker brands or less disciplined cultivation may see share loss before they see any regulatory relief.

The contrarian miss is cash conversion: operating cash burn still isn’t behaving like a scaling operator, and the balance-sheet runway only helps if working capital normalizes rather than re-accelerates with growth. The bullish thesis is falsified if adjusted EBITDA remains negative into fiscal Q3 or if the announced European shipments slip, because then the market will re-rate this as another cannabis restructuring story rather than a true margin inflection. On the other hand, if EU GMP lands and the margin bridge holds, the stock can de-rate the sector’s “permanent dilution” discount.

Key Decisions for Investors

• Long CGC common for 4-8 weeks into the next operating update; the setup is for a catalyst-driven rerating if management can show gross margin holding above the low-30s and no cash-burn slippage. Risk/reward is favorable only if you define risk tightly around a failed Q2/Q3 cultivation read-through.
• Buy CGC Jan-2027 calls or call spreads instead of common equity if you want exposure to the EU GMP and UK shipment catalysts with limited balance-sheet risk. This is a better expression than stock if you believe the inflection is real but timing is noisy.
• Pair trade: long CGC / short TLRY over the next 1-3 months to isolate Europe + cultivation execution versus a more diversified but less differentiated cannabis platform. Falsify the pair if CGC misses the mid-30s margin target or if TLRY prints a materially stronger international growth update.
• Watch-item, not trade: if fiscal Q2 operating cash outflow does not improve materially, treat any rally as a sell-the-pop event. A sustained cash burn above the current quarter’s implied run-rate would likely cap multiple expansion regardless of revenue growth.